Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4552562 | 1.00 | CASP3 (0.71) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL31498750 | 1.00 | CASP3 (0.71) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL12287655 | 0.90 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL5497707 | 0.90 | CASP3 (0.62) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL5497705 | 0.90 | CASP3 (0.62) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL27604454 | 0.90 | CASP3 (0.62) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL14160419 | 0.89 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL22960726 | 0.89 | CASP3 (0.69) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL33377838 | 0.89 | CASP3 (0.69) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL13573587 | 0.89 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023108031-A1 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | CYTOSITE BIOPHARMA INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20100183635-A1 | GLYCOSYLATED SPECIFICITY EXCHANGERS | TRIPEP AB (SE) | 2010-07-22 | — | — | US | disclosed |
| US-7622440-B2 | Cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2009-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183635-A1 | GLYCOSYLATED SPECIFICITY EXCHANGERS | SLC17A5, ASGR1, SLC2A1 | CASP3 4878/4885KMT2A 3462/4885MDM4 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.